These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowskal H; Strzelczyk J; Janiak A; Malecka-Panas E Hepatogastroenterology; 2006; 53(70):608-12. PubMed ID: 16995472 [TBL] [Abstract][Full Text] [Related]
6. Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods. Eskelinen MJ; Haglund UH Eur J Surg; 1999 Apr; 165(4):292-306. PubMed ID: 10365829 [TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229 [TBL] [Abstract][Full Text] [Related]
17. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Singh P; Srinivasan R; Wig JD Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535 [TBL] [Abstract][Full Text] [Related]
18. Genetic basis of cancer of the pancreas: diagnostic and therapeutic applications. Sakorafas GH; Tsiotou AG Eur J Surg; 1994 Oct; 160(10):529-34. PubMed ID: 7849153 [TBL] [Abstract][Full Text] [Related]
19. Adenoviral gene therapy for pancreatic cancer: where do we stand? Kuhlmann KF; Gouma DJ; Wesseling JG Dig Surg; 2008; 25(4):278-92. PubMed ID: 18635930 [TBL] [Abstract][Full Text] [Related]